Holen Sie sich die Stockscreener-App
6.35
5.93%
-0.40
Vorhandelsmarkt:
6.38
0.03
+0.47%
Schlusskurs vom Vortag:
$6.75
Offen:
$6.73
24-Stunden-Volumen:
1.57M
Relative Volume:
1.40
Marktkapitalisierung:
$328.28M
Einnahmen:
$170.44M
Nettoeinkommen (Verlust:
$-193.88M
KGV:
-1.6915
EPS:
-3.7541
Netto-Cashflow:
$-126.38M
1W Leistung:
+11.01%
1M Leistung:
-32.01%
6M Leistung:
-46.19%
1J Leistung:
-35.60%
1-Tages-Spanne:
$6.305
$6.88
1-Wochen-Bereich:
$5.455
$6.88
52-Wochen-Spanne:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
6.35 | 348.96M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO, Novartis, Dyne near FDA submissions in muscular dystrophies - BioSpace
RGNX stock on track for worst day ever as big Q1 loss, cash concerns eclipse Duchenne trial success - MSN
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
REGENXBIO to push for accelerated approval of DMD gene therapy - MSN
RGNX: Rolling BLA for Duchenne gene therapy set for Q3 2024, with robust data and regulatory momentum - TradingView
Before Buying Regenxbio Inc (RGNX) Stock, Check Out the Cash Runway - Insider Monkey
RegenXbio’s RGX-202 Pivotal Win Lifts Outlook - TipRanks
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2026 Earnings Call Transcript - Insider Monkey
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
RegenXBio’s Earnings Call Signals Pivotal Gene-Therapy Win - TipRanks
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
Biotech REGENXBIO lines up May investor talks in New York and online - Stock Titan
Gene therapy innovation gains momentum at REGENXBIO during ASGCTherapy event - Traders Union
Regenxbio slides after late-stage trial data for Duchenne therapy - MSN
StockWatch: Regenxbio Tumbles Despite Positive Pivotal Data for DMD Gene Therapy Candidate - Genetic Engineering and Biotechnology News
What's Behind Regenxbio's Recent Plunge - Kavout
REGENXBIO Inc stock (US75901B1052): gene therapy pipeline in focus after recent data update - AD HOC NEWS
REGENXBIO: 'Hold' On RGX-121 CRL MPS II And RGX-202 DMD Results (NASDAQ:RGNX) - Seeking Alpha
RegenXBio (RGNX) Gets a Buy from RBC Capital - The Globe and Mail
RGNX Technical Analysis & Stock Price Forecast - Intellectia AI
RGNX Maintained by B of A Securities -- Price Target Lowered to $14 - GuruFocus
Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Sarepta's Elevidys Faces 'Little' Pressure After Regenxbio Data, Wedbush Says - Moomoo
REGENXBIO Is Maintained at Overweight by Barclays - Moomoo
RGNX Maintained by Barclays -- Price Target Lowered to $12 - GuruFocus
A Quick Look at Today's Ratings for Regenxbio(RGNX.US), With a Forecast Between $12 to $42 - Moomoo
Goldman Sachs Maintains Regenxbio(RGNX.US) With Hold Rating, Cuts Target Price to $10 - Moomoo
Nasdaq Jumps Over 200 Points; Dillard's Shares Gain After Q1 Earnings - Sahm
Discipline and Rules-Based Execution in RGNX Response - Stock Traders Daily
Barclays Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval - Sahm
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty - Investing.com
Goldman Sachs lowers Regenxbio stock price target on regulatory uncertainty By Investing.com - Investing.com Canada
Regenxbio posts mixed Phase III data on RGX-202 - The Pharma Letter
Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to FDA Approval - GuruFocus
REGENXBIO (RGNX) Reports Positive Data from RGX-202 Trial - GuruFocus
Regenxbio (RGNX) Q1 Loss Deepens And Reinforces Bearish Cash Runway Concerns - simplywall.st
REGENXBIO advances Duchenne gene therapy toward accelerated approval - MSN
REGENXBIO 1Q Loss/Shr $1.72 >RGNX - Moomoo
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):